Emily Chan

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Yibing Yan et al. · Nature · 2012 · 1.1K citations · Full text

Medicine, Kinase Inhibitors, Anti-cancer Agent +6

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Marc Peeters, Timothy Price, Andrés Cervantes et al. · Journal of Clinical Oncology · 2010 · 992 citations

Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial

Julio García‐Aguilar, Lindsay A. Renfro, Oliver S. Chow et al. · The Lancet Oncology · 2015 · 412 citations · Full text

Surgical Oncology, Radiation Therapy, Gastrointestinal Oncology +12

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

Marc Peeters, Timothy Price, Andrés Cervantes et al. · Annals of Oncology · 2013 · 219 citations · Full text

Gastrointestinal Oncology, Medicine, Pharmacology +9

Rectal Cancer, Version 2.2015

Al B. Benson, Alan P. Venook, Tanios Bekaii‐Saab et al. · Journal of the National Comprehensive Cancer Network · 2015 · 214 citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Colorectal Surgery +15